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Azole derivatives, such as ketoconazole and bifonazole, are 
well-established antifungal drugs. Recently, these com-
pounds have been reported to have therapeutic efficacy also 
in inflammatory skin disorders. There is increasing evidence 
that calmodulin is involved in fungal infections as well as in 
inflammatory skin diseases. Therefore, we investigated the 
effects of various antifungal drugs on calmodulin activity, 
using calmodulin-dependent phosphodiesterase as an indica-
tor for the calmodulin activity. All azole derivatives tested 
A zole derivatives, such as bifonazole and ketoconazole, have long been used as potent antifungal drugs (for reviews, see [1,2]). In recent case reports and clinical trials, bifonazole and ketoconazole have also been re-ported to be of therapeutic value in inflammatory skin 
diseases, such as seborrheic dermatitis [3-10]. Furthermore, bifona-
zole has been shown to exert direct anti-inflammatory activity in 
histamine-induced erythema [11]. The mechanism of action sug-
gested for the antifungal activity of azole derivatives is the inhibi-
tion of ergosterol biosynthesis, an essential step in the membrane 
formation of fungal cells, resulting in the fungistatic activity of 
azole derivatives [12] . However, this mechanism cannot explain the 
direct anti-inflammatory properties of the azole derivatives, particu-
larly of bifonazole, which have been observed in clinical trials 
[10,11,13] and animal studies [14]. 
Calmodulin (CaM), a calcium-binding protein that shows a 
highly conserved structure in different tissues and in a large variety 
of species, is involved in the regulation of various cellular responses, 
including prostaglandin synthesis and histamine release from mast 
cells (for review, see [15]). Furthermore, increased levels of CaM 
have been shown to be associated with dermatologic diseases char-
acterized by inflammation of the skin, such as psoriasis [16,17]. In 
recent studies, evidence has been obtained that CaM might be in-
volved in the regulation of yeast-mycelial transition of Candida 
albicans [18,19]. This morphogenesis is thought to be a critical step 
in the pathogenesis of fungal infections [20]. Accordingly, we have 
investigated the ability of various antifungal drugs, five azole deriva-
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Abbrevia tions: 
CaM: calmodulin 
ICso : 50% inhibitory concentration 
POE: cyclic 3': 5'-nucleotide phosphodiesterase 
competitively inhibited calmodulin activity with 50% inhibi-
tory concentration values in the low micromolar range. In 
contrast, antifungal drugs belonging to other chemical 
classes did not display inhibitory activity. Thus, this study 
provides evidence that direct interaction with calmodulin 
might contribute to the therapeutic activity of azole deriva-
tives, particularly to their efficacy in the treatment of inflam-
matory skin disorders. ] I,1vest Dermatol1 00:343 -346, 1993 
tives and six non-azole antifungals, to inhibit CaM activity, using 
CaM-dependent cyclic 3': 5'-nucleotide phosphodiesterase (PDE) 
as an indicator enzyme. 
MATERIALS AND METHODS 
CaM activity was measured based on its activation of cyclic 3' : 5'-
nucleotide phosphodiesterase (CaM-dependent PDE) from beef 
heart (Boehringer Mannheim, Indianapolis, IN), using [3H]adeno-
sine 3' : 5'-cyclic monophosphate as substrate (NEN Du Pont, Wil-
mington, DE), as previously described in detail [21]. CaM-indepen-
dent PDE from the same donor tissue (Boehringer Mannheim, 
Indianapolis, IN) was used as a control. In the case of CaM-depen-
de.nt PDE, th~ assay was performed in the presence of 10 ng CaM 
(Sigma Chemical Co., St. LoUls, MO) in 500,u1 incubation volume, 
unless otherwise indicated. This CaM concentration yielded about 
80% of the maximum enzyme activity. After an incubation period 
of 20 min at 37 0 C, the reaction was terminated by addition of zinc 
sulf~te.' and the.reactio.n product, adenosine 5'-monophosphate, was 
preCipitated With banum hydroxide according to the method of 
Pbch [22]. ~ftercel:tri~ugation, the remaining substrate was quanti-
fied by hqUld scmttllatlon counting. 
The antifungal drugs tested were dissolved in dimethyl sulfoxide 
(DMSO), kept under light protection, and diluted to a final DMSO 
concentration of 0.1 % in the assay. This concentration of DMSO 
did .not affect .the enzyme activity. Each drug was tested in concen-
trations rangmg from O.l,uM to 1 mM. All incubations were 
performed in triplicate and the drugs were tested in at least three 
independent experiments. All drugs, with the exception of keto-
conazole, were obtained from Sigma Chemical Co. (St. Louis, MO). 
Ketoconazole was a generous gift of The Janssen Research Founda-
tion (Beerse, Belgium). 
RESULTS 
Various antifungal drugs with different chemical structures were 
tested on their ability to antagonize CaM activity. Polymyxin B, 
which is known to be a potent and selective antagonist of CaM [21], 
was used as the control. Most drugs, even at high concentrations of 
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Figure 1. Inhibition of calmodulin-dependent phosphodiesterase, used 
as an indicator enzyme for calmodulin activity, by various antifungal 
drugs: 1) 5-fluorocytosine, 2) amphotericin B, 3) nystatin, 4) tolnaftate, 5) 
clotrirnazole, 6) polymyxin B (used as a reference antagonist) [21] . The 
results shown are means of three to five independent experiments, each 
performed in triplicate. 
1 mM, only marginally inhibited CaM-dependent PDE (Fig 1, 
Table I), which was used as an indicator enzyme for CaM activity. 
However, the azole derivative clotrimazole effectively inhibited 
CaM-dependent PDE in a dose-dependent manner, displaying a 
half-maximal inhibition at a drug concentration (50% inhibitory 
concentration (ICso) value) of 18.4 ± 4.6,uM (n = 5) . Similar re-
sults were obtained with all azole derivatives (Table II), which were 
found to inhibit CaM-dependent PDE in a dose-dependent manner 
(Table I) with ICso values in the low micromolar range. The least 
effective derivative was ketoconazole (ICso value, 65.2 ± 12.3 ,uM; 
n = 4). 
Inhibition of CaM-dependent PDE could be based on two dif-
ferent modes of action, direct antagonism of CaM or interference 
with the detection enzyme, PDE, particularly with its binding site 
for the substrate, adenosine 3' : 5' -cyclic monophosphate. To inves-
tigate these two possibilities, we compared the effects of each azole 
derivative on the CaM-independent and CaM-dependent isoen-
zyme from the same donor tissue. As shown for bifonazole (Fig 2), 
the drug inhibited both isoenzymes but much higher concentra-
tions were required to inhibit CaM-independent PDE to the same 
extent as CaM-dependent PDE, which was reflected by the differ-
ent ICso values for both enzymes, 380.0 ± 26.9 ,uM (n = 5) and 
14.1 ± 2.7 ,uM (n = 5), respectively. A comparable selectivity for 
CaM-dependent PDE was observed with all azole derivatives (Table 
II), indicating that drug-induced inhibition of CaM-dependent 
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Table II. Inhibition of Calmodulin (CaM)-Dependent and 
-Independent Phosphodiesterase by Azoles Derivatives· 
Phosphodiesterase 
Drug CaM Dependent CaM Independent Selectivity 
Bifonazole 14.1 ± 2.7 380.0 ± 26.9 27.0 
Miconazole 11.3 ± 3.3 172.3 ± 18.6 15.3 
Econazole 6.3 ± 1.9 208.3 ± 38.6 33.1 
Clotrimazole 18.4 ± 4.6 >1000.0' >54.3 
Ketoconazole 65.2 ± 12.3 262.5 ± 25.3 4.0 
• The values indicate the concentrations (in tiM) that induced 50% inhibition of 
enzyme activity (mean ± SEM in three to six independent experiments, each per-
formed in triplicate) . The selectivity of these compounds towards the CaM-depen-
dent isoenzyme, as compared to the CaM-independent isoenzyme, was calculated as 
the ratio of the corresponding IC,. values. 
• Higher concentrations of c1otrimazole were partially insoluble; 1 mM c1otrima-
zole induced inhibition of CaM-independent phosphodiesterase by 28.3 ± 2.4% of 
the control. 
PDE was due to interference with CaM rather than by direct inhibi-
tion of the apoenzyme, PDE. However, the individual selectivity 
was found to vary between the different drugs. Clotrimazole dis-
played the highest selectivity of more than 55 times, whereas 
ketoconazole was the least selective drug, being only about four 
times more potent on CaM-dependent than on CaM-independent 
PDE. 
The interaction of the azole derivatives with CaM was further 
investigated by performing dose-response curves in the presence of 
increasing concentrations of CaM (10, 200, or 500 ng) for each 
azole derivative. As shown in Fig 3 for bifonazole, enzyme inhibi-
tion was reversed by increasing concentrations of CaM present in 
the assay, as reflected by the characteristic shift of the dose-response 
curve to the right. Similar results were obtained with all azole deriv-
atives, indicating a competitive interaction of these drugs with 
CaM. This finding was further supported by a kinetic analysis of the 
inhibition of CaM-dependent PDE by bifonazole using a double-
reciprocal Lineweaver-Burk plot (Fig 4). This plot demonstrates 
that the maximum enzyme activity remained unaltered in the pres-
ence of the drug, whereas higher concentrations of CaM were neces-
sary to stimulate the enzyme. This finding characterizes the drug as 
a competitive inhibitor of CaM. 
DISCUSSION 
In the present study, we have investigated the ability of various 
structurally unrelated drugs to antagonize CaM activity. The azole 
derivates, bifonazole, econazole, miconazole, clotrimazole, and ke-
toconazole, were all found to inhibit CaM in a dose-dependent 
manner. Inhibition of CaM-dependent PDE was selective with re-
spect to the CaM-independent isoenzyme and competitive versus 
Table I. Effects of Various Antifungal Drugs on Calmodulin Activity· 
Drug 1 JiM 10 JiM 100 JiM 1 mM 
Ciclopiroxolarnine 2.16 ± 0.02 2.07 ± 0.07 1.94 ± 0.15 1.04 ± 0.14 
Nystatin 2.16 ± 0.01 1.99 ± 0.10 1.67 ± 0.05 1.41 ± 0.22 
Amphotericin B 2.15 ± 0.02 2.13 ± 0.03 2.04 ± 0.03 1.96 ± 0.12 
5-fluorocytosine 2.16 ± 0.02 2.07 ± 0.05 2.01 ± 0.04 2.02 ± 0.09 
Tolnaftate 2.01 ± 0.04 1.99 ± 0.03 2.00 ± 0.05 1.41 ± 0.12 
Griseofulvin 2.14 ± 0.02 2.07 ± 0.06 1.96 ± 0.06 1.44 ± 0.08 
Bifonazole 2.01 ± 0.08 0.84 ± 0.05 0.07 ± 0.04 0.00 ± 0.01 
Miconazole 1.91 ± 0.05 0.82 ± 0.04 0.29 ± 0.04 0.05 ± 0.02 
Econazole 1.77 ± 0.04 0.68 ± 0.07 0.17 ± 0.05 0.08 ± 0.02 
Clotrirnazole 1.96 ± 0.03 0.89 ± 0.18 0.39 ± 0.04 0.16 ± 0.09 
Ketoconazole 2.09 ± 0.03 1.63 ± 0.06 0.88 ± 0.04 0.30 ± 0.02 
• CaM activity, measured in the presence of various drug concentrations, was detected by its ability to stimulate CaM-dependent phosphodiesterase. The values indicate the 
phosphodiesterase activity (mean ± SEM from three to five independent experiments, each performed in triplicate) expressed as nmol adenosine 3' : 5' -cyclic monophosphate 
(cAMP) hydrolysed/min/mg enzyme. In the absence of drugs, the enzyme activity was 2.18 ± 0.24 nmol cAMP/min/mg. 
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Figure 2. Inhibition of calmodulin-dependent (e) and -independent (II) 
phosphodiesterase by bifonazole, a representative azole derivative. 
Values are means ± SEM from five independent experiments, each per-
formed in triplicate. The absence of error bars indicates that the SEM was 
smaller than the symbol. 
CaM. In contrast, the non-azole antifungal drugs tested, amphoter-
icin B, tolnaftate, griseofulvin, 5-fluorocytosine, nystatin, and ci-
clopiroxolamine, did not express significant inhibitory activity. 
The finding that the azole derivatives are competitive antagonists 
of CaM appears to be relevant to their clinical efficacy in two differ-
ent contexts . Firstly, recent reports have suggested that CaM plays a 
regulatory role in the pathogenesis of infections by C. albicalls. CaM 
has been partially purified from this yeast [23] and well character-
ized CaM antagonists, trifluoperazine [18,19] and R 24571 [19]' 
have been found to inhibit yeast-mycelial transition, a critical step in 
the mechanism of infections by C. albicalls [20]. Although the azole 
derivatives are believed to exert their antifungal efficacy by inhibi-
tion of ergosterol biosynthesis, thus interfering with the membrane 
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Figure 3. Dose-response curve of bifonazole on calmodulin-dependent 
phosphodiesterase in the presence of various concentrations of calmodu-
lin (A, 10; e, 200; _, 500 ng per 500 III assay volume). The data 
(means ± SD of triplicate assays) are derived from a representative exper-
iment (n = 3). The absence of error bars inclicates that the SD was smaller 
than the symbol. Similar results were obtained with other azole deriva-
tives tested. 
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Figure 4. Competitive interaction of bifonazole with calmodulin. Kinetic 
analysis (Linewea,:,er-Burk ,Plot) of data (means of triplicate) obtained 
fr?m a .representative expenment (n = 3). The lilies represent values, ob-
tamed m the presence of 0 (_), 10 (e), or 30 (A) j.lM bifonazC?le. 
study, might potentially contribute to their antifungal activity 
towards a broad spectrum of fungi. 
. Secondly, the azole derivatives, particularly ketoconazole and 
?Ifonazole, have .bee~ reported to be of therapeutic value in various 
1I1flammatory sk1l1 diseases . In clinical trials, bifonazole has been 
shown to be effective in the treatment of sebopsoriasis and rosacea 
[10]. Furthermore, bifonazo!e [3,6,9,10] and ketoconazole [4,5 ,7,8] 
have successfully been used 111 the treatment of seborrheic dermati-
tis. The common feature of these diseases is inflammation. In addi-
tion, sebopsoriasis and seborrheic dermatitis are characterized by 
hyperproliferatlOn of the epidermis. The numerous cellular func-
tions,. in which CaM. has ~een demonstrated to playa regulatory 
role, 1I1clude cell proliferation a.nd inflammatory responses (for re-
vle~, s~e [15]~ . There~ore, the direct inhibition of CaM by the azole 
denvatlv~s ml~ht be 111 part the mechanism by which these drugs 
exert their antl-1I1flammatory activity . 
The drug concentrations applied clinically, i.e., 1 % bifonazole 
and 2% ket?conazole, equal a~out 32 mM and 38 mM, respec-
t~vely . CO~1S1denng the high sk1l1 penetration of the azole deriva-
tives, speclfical.ly ofblfonazole (for review, see [2]), and a life-time 
of t~ese dru~s 111 the skin ~f more than 30 h [20J , the drug concen-
~rat~ons achieve? aft~r t~plcal application appear to be sufficient to 
1I1hlblt CaM activity m IJ/IJO. The potencies of the azole derivatives as 
C~ antag~nists are comparable to those of the naphthalenesulfon-
amldes~ wh~ch. are "classical" CaM antagonists [24] , and to that of 
the antlpsonatlc d~g, anthralin [25J. In conclusion, the present data 
raise the hypotheSIS that direct 1l1teractions of azole derivatives with 
CaM might contribute to the anti-inflammatory and antifungal 
activity of these drugs. 
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